Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CR-001 in Advanced Solid Tumors
NCT07335497Phase 2Recruiting
- Sponsor
- Crescent Biopharma
- Start
- Feb 2026
- Primary completion
- Feb 2029
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 9
01
Overview
A Phase 2 trial of CR-001 in solid tumor, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), biliary tract cancer (BTC), endometrial carcinoma, sponsored by Crescent Biopharma. Started Feb 2026; status: recruiting.
02
Drugs
CR-001
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)biliary tract cancer (BTC)endometrial carcinoma
Beyond the preview
Go deeper on NCT07335497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07335497.